Considering regorafenib's capacity to enhance immune cell infiltration, upregulate tumor cell MHC, and downregulate PD‐L1 expression, we subsequently evaluated the potential of Neo‐CRCVAS combined with regorafenib (RegoNeo) to elicit tumor‐specific immune responses. Here, CD274 is linked to neoplasm.